Form 8-K uniQure N.V. For: Aug 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
RBC Capital on uniQure BV (QURE): 'Brain Safety Signal Unfortunate, But Stock Reaction Overdone'
August 8, 2022 12:59 PM EDTRBC Capital analyst Luca Issi reiterated an Outperform rating and $53.00 price target on uniQure BV (NASDAQ: QURE)
The analyst comments "Huntington's brain safety signal is unfortunate as it will delay the program, formal FDA clinical hold is possible and one patient has... More
Cowen on uniQure BV (QURE): 'We are hopeful the risk is manageable'
August 8, 2022 12:59 PM EDTCowen analyst Joseph Thome reiterated an Outperform rating on uniQure BV (NASDAQ: QURE).
The analyst comments "While the news is unfortunate and warrants additional investigation, we note that the U.S. data update remains on track for Q2:23 and a total of... More
Goldman Sachs Reiterates Buy Rating on uniQure BV (QURE)
August 8, 2022 12:57 PM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $51.00 price target on uniQure BV (NASDAQ: QURE).
The analyst comments "QURE released 2Q EPS and announced the postponement of procedures in the higher-dose cohort (6x1013vg) of the Ph1/2 US and Ph1b/2 EU studies of gene therapy AMT-130 in Huntingtons disease due to suspected unexpected... More
Credit Suisse Reiterates Outperform Rating on uniQure BV (QURE), 'Catalysts On-Track'
August 8, 2022 12:54 PM EDTCredit Suisse analyst Judah C. Frommer reiterated an Outperform rating and $51.00 price target on uniQure BV (NASDAQ: QURE)
The analyst comments "With 2Q22 earnings QURE disclosed pausing of enrollment in the high-dose cohort of its Ph1/2 AMT-130 (Huntingtons GT) trial following DSMB recommendation tied to 3 suspected unexpected severe adverse... More
